NextCure's Immunomedicine NC410 Shows Promising Anti-Cancer Activity In Preclinical Studies

  • NextCure Inc NXTC has published preclinical data for NC410 in the online journal eLife.
  • NC410 is currently being evaluated in a Phase 1/2 trial in patients with advanced or metastatic solid tumors. Initial data readout expected in half of 2021.
  • Data revealed that NC410 promotes T cell-mediated anti-tumor immunity and infiltration and localized activity of T cells in the tumor microenvironment, suggesting its potential both as monotherapy and combination treatment.
  • This publication demonstrated that NC410 binding was most notable in collagen-rich tumors, such as gastric, ovarian, lung, head & neck, and regions where immune cells were excluded. 
  • NC410 is a dimeric LAIR-2 Fc fusion protein designed to act as a LAIR-1 decoy by binding with higher affinity to tumoral collagens than human LAIR-1, preventing LAIR-1-mediated immune suppression. 
  • Price Action: NXTC shares closed at $7.91 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefscancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!